Shattuck Labs Inc (STTK) — Titan Protect Analysis

STTK

Shattuck Labs Inc

Healthcare · ·

$4.58

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$377M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-9.60

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-61.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$12.50

+173% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 6 analysts covering this stock

About Shattuck Labs Inc

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also

https://www.shattucklabs.com

Country: United States Employees: 40 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.426

Positive but modest risk-adjusted returns

Kelly Fraction

0.0102

Marginal edge — very small allocation suggested

Calmar Ratio

-0.217

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-19.5%

Historical annualised return based on price data

Max Drawdown

-90.1%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

143

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.19

Moves slightly more than the broader market

52W High

$8.33

45% below the year high

52W Low

$0.71

543% above the year low

Avg Volume

617,850

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.56

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

3.02

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

-297.8%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-5,258.3%

Profit from core operations before interest and tax

Free Cash Flow

$-22,423,376

Negative — the business is spending more than it generates

Revenue (TTM)

$1M

Total revenue over the last 12 months

Net Income

$-49,874,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$18.00

Target Median

$12.50

Target Low

$7.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go